Home
Live Updates
Dr Kopetz on the Background of the KRYSTAL-1 Trial in KRAS G12C+ mCRC : vimarsana.com
Dr Kopetz on the Background of the KRYSTAL-1 Trial in KRAS G12C+ mCRC
Scott Kopetz, MD, PhD, FACP, discusses using adagrasib plus cetuximab in patients with metastatic colorectal cancer harboring KRAS G12C mutations.
Related Keywords
Texas ,
United States ,
Scott Kopetz ,
University Of Texas Md Anderson Cancer Center ,
Translational Integration ,
Cancer Center ,
He University Of Texas Md Anderson Cancer Center ,
Onclive Tv ,
Colorectal Cancer ,
vimarsana.com © 2020. All Rights Reserved.